Navigation Links
Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
Date:11/21/2007

LAVAL, QC, Nov. 21 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it has received a written response from the U.S. Food and Drug Administration (FDA) regarding its appeal of the Agency's Approvable Letter for its once-daily tramadol formulation through the Formal Dispute Resolution process. In the response, the Acting Director of the Office of Drug Evaluation II, Center for Drug Evaluation and Research has not overturned the decision in the Agency's Approvable Letter of May 2007.

Labopharm plans to appeal the matter to the next supervisory level at the FDA in the coming weeks.

Labopharm initiated the Formal Dispute Resolution process in October of this year after receiving an Approvable Letter from the FDA for its once-daily formulation of tramadol in May.

About the FDA's Formal Dispute Resolution Process

FDA regulations provide a mechanism for those seeking regulatory approval of a drug product through a New Drug Application (NDA) to obtain formal review of any Agency decision through a Formal Dispute Resolution process by raising the matter with the supervisor of the employee who made the decision. If the issue is not resolved at the primary supervisory level, the applicant may request that the matter be reviewed at the next higher supervisory level. This process may continue through the Agency's chain of command, through the Centers to the Commissioner of Food and Drugs. The Formal Dispute Resolution process exists to encourage open, prompt discussion of scientific (including medical) disputes and procedural (including administrative) disputes that arise during the drug development, new drug review, generic drug review, and post-marketing oversight processes.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily fo
'/>"/>

SOURCE Labopharm Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
9. DaVita Receives Civil Complaint
10. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
11. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... NY (PRWEB) June 03, 2015 Acne is ... (“bacne”) can be particularly stubborn to eliminate and hard to ... most common in teens and young adults, in the years ... produce sebum, or oil,” says Jayme Bashian, director and lead ... characteristic pimples, blackheads and cysts of acne are caused by ...
(Date:6/3/2015)... 03, 2015 Fourroux Prosthetics, located at ... will celebrate its grand opening with a ribbon cutting ... prosthetic center of its kind in the area, Fourroux ... care and outcomes through use of patented advanced prosthetics ... CEO of Fourroux Prosthetics, states, “Our goal has always ...
(Date:6/3/2015)... Implant design can have a profound influence on ... to an implant surface. The unique triangular-shape of the ... bone regeneration, resulting in the gain of greater volume ... for more esthetic restorations. , “It’s all in the ... The triangular neck of the V3 provides solid anchorage ...
(Date:6/3/2015)... These are challenging and unpredictable times ... number of digital-first business are rewriting the rules for ... serious need for traditional businesses to take on a ... deliver their services. On top of this there ... technology start-ups, to bring new innovation and approaches to ...
(Date:6/3/2015)... DailyEndorphin is pleased to announce the launch ... this highly configurable new offering, DE's annual clients may ... of its wellness programming for the entire year as ... this new module, annual clients may also do the ... surveys, (3) Continually report on participant progress towards the ...
Breaking Medicine News(10 mins):Health News:Back Acne: Tips for Clearer Summer Skin 2Health News:Back Acne: Tips for Clearer Summer Skin 3Health News:Fourroux Prosthetics Atlanta to Have Grand Opening Gala & Ribbon Cutting Ceremony 2Health News:MIS Implants Launches Radically New V3 Dental Implant For Immediate Biological Benefits 2Health News:Chief Digital Officer of Travelex joins Bayer, Abellio and Just Eat at The Open Mobile Summit London 2Health News:DailyEndorphin Launches Wellness "Events" Portal 2
... in the March 2006 issue of Archives of Ophthalmology says ... risk of relapse of a vision-threatening eyelid condition called trichiasis.// ... clinical trial funded by the National Eye Institute (NEI), part ... ,It was found that azithromycin was better than the local ...
... Medicine in St. Louis say that a noninvasive approach ... developing drugs for cystic fibrosis and pneumonia. // Positron ... induced inflammation in the lungs of healthy volunteers. ... a new drug decreased lung inflammation, the options for ...
... you can’t wait for a appointment a local clinic now ... clear results in 10 minutes//, ,Chlamydia is the most ... no symptoms, and can be passed on to others without ... including problems in pregnancy and infertility in both men and ...
... long term will make the brain to lose its ability, gradually ... led by Lambros Messinis at the University Hospital of Patras in ... taken marijuana heavily. They smoked at least four joints a week ... New Scientist. ,Their brains were rustier than those ...
... is found to improve their kidney function in patients with heart ... he said that those patients who took 80 mg of the ... ,The drug is the world's top-selling prescription drug. The data of ... scientific meeting in Atlanta. ,50% of the patients, who ...
... Jordan said that the kingdom was untouched by the avian flu ... the joint effort of both the public and the government. He ... in the country. , The minister made the ... , In that occasion to celebrate this great achievement the ...
Cached Medicine News:Health News:Home Chlamydia Test 2
(Date:6/2/2015)... 2015 The Canadian Society for Vascular Surgery (CSVS) ... or procedures that are commonly ordered but not ... Choosing Wisely Canada.  The list identifies five (5) ... patients and physicians about what care is really ... Surgery,s list identified the following five (5) recommendations: ...
(Date:6/2/2015)... 02, 2015 Research and Markets ( http://www.researchandmarkets.com/research/g5r2nj/surgical_incision ) ... - Global Strategic Business Report" report to their offering. ... US, Canada , Japan ... , Latin America , and Rest of ... Surgical Incision Closures in US$ Million by the following Product ...
(Date:6/2/2015)... RALEIGH, N.C. , June 2, 2015 BioDelivery ... to weather conditions, the presentation by Dr. Mark A. ... been changed to 2:30 PM Eastern time. Jefferies ... Time Grand Hyatt, New York City ... and can be accessed at www.bdsi.com .  For those ...
Breaking Medicine Technology:As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 2As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 3As part of the Choosing Wisely Canada campaign the Canadian Society for Vascular Surgery releases list of commonly used tests and treatments to question 4Surgical Incision Closures - Global Strategic Business Report 2015 2BioDelivery Sciences to Present at the Jefferies 2015 Healthcare Conference - Schedule Change 2BioDelivery Sciences to Present at the Jefferies 2015 Healthcare Conference - Schedule Change 3
... Benefit over Placebo Larger at One Year than ... 11, 2007,/PRNewswire-FirstCall/ -- Medivation, Inc. today announced that ... Phase 2 study in mild-to- moderate Alzheimer's,disease were ... months. Importantly, on every endpoint studied, the benefits,of ...
... Study Presented at Federation of,Clinical Immunology Societies ... 11, 2007 /PRNewswire-FirstCall/ --,Orchestra Therapeutics, Inc. (Bulletin ... its completed Phase II open-label study of,NeuroVax(TM), ... for the treatment of relapsing-remitting multiple sclerosis,(MS). ...
Cached Medicine Technology:Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 2Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 3Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 4Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 5Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy 6Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 2Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 3Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 4Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 5
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: